Precigen (PGEN) Q4 2024 earnings summary

Executive summary

• PRGN-2012 advanced from discovery in 2020 to BLA submission in 2024, receiving FDA priority review with a PDUFA date of August 27, 2025, and no advisory committee planned.

• Pivotal clinical data for PRGN-2012 showed a 51% complete response rate, durable efficacy, and significant reduction in surgeries, with all phase I responders surgery-free for three years.

• Commercial and manufacturing readiness for PRGN-2012 is advanced, with a dedicated team, partnership with EVERSANA, and a focus on 500 key otolaryngologists for a 2025 launch.

• Confirmatory trial for PRGN-2012 is underway, enrolling 35 patients in a single-arm design, with data expected in 2026–2027.

• Cash runway extended into 2026 following $87.5M capital raise and sale of non-core IP and royalty rights.

Financial highlights

• Net loss for 2024 was $126.2 million ($0.47 per share), compared to $95.9 million ($0.39 per share) in 2023, with over $55 million of 2024 loss as non-cash charges.

• Ended 2024 with $97.9 million in cash, cash equivalents, and investments, expected to fund operations well into 2026.

• Cash burn for 2024 totaled $76.8 million.

• Total revenues decreased 37% year-over-year to $3.9 million, mainly due to lower Exemplar product/service volumes.

• Research and development expenses rose 9% to $53.1 million, driven by PRGN-2012 trial and manufacturing costs.

Outlook and guidance

• Commercial revenues from PRGN-2012 expected to begin in the second half of 2025, contingent on FDA approval.

• Financial runway projected to extend beyond anticipated launch and into 2026, including expected product revenue.

• Ongoing confirmatory trial for PRGN-2012 and continued development of PRGN-2009 and PRGN-3006 programs.